



Published in final edited form as:

Pancreas. 2018 ; 47(10): 1180–1184. doi:10.1097/MPA.0000000000001176.

Accelerating the Drug Delivery Pipeline for Acute and Chronic Pancreatitis

Maisam Abu-El-Haija, MD^{*,†}, Anna S Gukovskaya, PhD^{‡,§}, Dana K. Andersen, MD^{||}, Timothy B. Gardner, MD, MS[¶], Peter Hegyi, MD, PhD, DSc^{#,}, Stephen J Pandol, MD^{††}, Georgios I. Papachristou, MD, PhD^{‡‡,§§}, Ashok K Saluja, PhD^{|||}, Vikesh K Singh, MD, MSc^{¶¶}, Aliye Uc, MD^{##}, and Bechien U. Wu, MD, MPH^{***}**

* Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

† Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH

‡ Department of Medicine, University of California, Los Angeles, Los Angeles, CA

§ Pancreatic Research Group, UCLA/VA Greater Los Angeles Healthcare System, Los Angeles, CA

|| Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD

¶ Department of Medicine, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine, Dartmouth University, Hanover, NH

MTA-SZTE Translational Gastroenterology Research Group, University of Szeged, Szeged, Hungary

** Institute for Translational Medicine and First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary

†† Division of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA

‡‡ Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA

§§ Division of Gastroenterology and Hepatology, Veterans Affairs Pittsburgh Health System, Pittsburgh, PA

||| Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL

¶¶ Division of Gastroenterology, Department of Medicine, University of Johns Hopkins, Baltimore, MD

Address correspondence to: Maisam Abu-El-Haija, MD, Associate Professor of Pediatrics, Medical Director, Pancreas Care Center, Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave MLC 2010, Cincinnati, OH 45229, Maisam.Haija@cchmc.org. Phone: 513-803-2123, Fax: 513-487-5528.

Disclosures:

Vikesh Singh is a consultant to Abbvie, Akcea Therapeutics and Ariel Precision Medicine; Aliye Uc is a member of American Board of Pediatrics, Subboard of Pediatric Gastroenterology; Georgios Papachristou received grant support by Abbvie & a consultant with GlaxoSmithKline and Abbvie.

Stead Family Department of Pediatrics, University of Iowa, Stead Family Children's Hospital, Iowa City, IA

***Center for Pancreatic Care, Department of Gastroenterology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA

Abstract

A workshop was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases to focus on research gaps and opportunities on drug development for pancreatitis. This conference was held on July 25th, 2018 and structured into three working groups (WG): Acute Pancreatitis (AP) WG, Recurrent Acute Pancreatitis WG and Chronic Pancreatitis WG. This paper reports the outcome of the work accomplished by the AP WG to provide the natural history, epidemiology, and current management of AP; inform about the role of preclinical models in therapy selection; and discuss clinical trial designs with clinical and patient reported outcomes to test new therapies.

Keywords

acute pancreatitis; drug therapy; trials; molecular targets

INTRODUCTION

Acute Pancreatitis (AP) is defined by meeting two out of the three criteria: abdominal pain and symptoms suggestive of pancreatitis, lipase and/or amylase three times the upper limit of normal, and image findings of AP.^{1,2} Acute pancreatitis is a leading cause of emergency department visits and gastrointestinal admissions in the United States (U.S.).³⁻⁵ Hospitalizations costs are well above \$2 billion annually.⁶ This constitutes a health and economic burden with increased hospitalizations, medications, lost work and school time for the patients and caregivers. There has been increasing trends in incidence of AP in adults with 30-100/100,000 (250,000 cases per year in the US alone,^{7,8} and in children up to 13/100,000/year.⁹⁻¹³ In most patients, pancreatic damage ultimately resolves, but in severe cases unremitting persistent systemic inflammatory response (SIRS) leads to multiple organ (especially lung) failure, a major cause of mortality among patients with AP. In adult cases, AP has a mortality rate of up to 6%,¹⁴ but as many as 50% of patients with severe disease associated with persistent multi-organ dysfunction have a risk of death.¹⁴⁻¹⁶ The majority of cases in children are mild, with a subset that progress to severe acute pancreatitis (SAP) with increased risk of complications, prolonged length of stay (LOS) and significant morbidity.¹⁷⁻¹⁹ Severe acute pancreatitis in children represents 15-30% of all cases depending on the definition used.²⁰⁻²³ With the rise in AP incidence, and its high morbidity rates,¹⁷⁻¹⁹ significant advances in prevention and treatment are urgent. However, we strongly believe that the incidence rate is still much higher than currently diagnosed. A multinational prospective clinical trial aiming to answer the real incidence rate of AP in children is in process (Pain in early phase of pediatric pancreatitis [PINEAPPLE] trial).²⁴

Pancreatitis has been associated with gallstones, alcohol abuse, hypertriglyceridemia, and genetic factors. Hallmark responses of AP include hyperamylasemia, inappropriate activation of digestive enzymes (e.g., conversion of trypsinogen to trypsin), accumulation of large vacuoles in acinar cells, induction of proinflammatory signals (e.g., the key transcription factor nuclear factor- κ B [NF- κ B]) resulting in inflammatory cell infiltration in the pancreas, a systemic inflammatory response and acinar cell death through apoptosis and necrosis.^{25,26} The pathogenesis of AP it is not fully understood, but evidence from basic science studies indicates critical roles for pathologic calcium signals, NF- κ B and zymogen activation.²⁷ Other observations in experimental and human AP have shown the formation of cytoplasmic vacuoles in acinar cells that represent disordered autophagy. Activation of trypsinogen to trypsin occurs then possibly through cathepsin B in these abnormal autophagic vacuoles.²⁸ Further, the mechanisms leading to trypsinogen activation as well as how trypsin causes AP are largely unknown. Recent insights into the pathogenic mechanism of pancreatitis provided novel information on role of acinar cell organelle disorders in AP.^{26,29}

Despite advances in understanding of the pathobiology of AP,²⁶ there is currently no pharmacologic therapy that has demonstrated efficacy in altering the natural history of the disease course. As a result, the mainstay of treatment continues to be entirely based on supportive care and management of complications.

A barrier to drug development in AP is the reduction in investment on novel drug research and development (R&D) that is part of a larger overall trend. Research investment in novel drug R&D decreased from \$21 billion (2004–2008) to \$17 billion (2009–2013). Unfortunately, the biggest decrease was in gastrointestinal (GI) diseases (62% from \$828 million to \$311 million). Furthermore, the relative research activity in pancreatitis dropped from 25.7% to 10.7% in the last 50 years compared to other GI inflammatory disorders.³⁰

The objectives of the AP working groups were to address four main domains pertinent to development of drug therapy in AP: (1) Natural history, epidemiology and current management, (2) Preclinical models, and animal models of AP, (3) Potential therapeutic targets, and (4) Risk stratification and patient selection.

NATURAL HISTORY AND CURRENT MANAGEMENT OF ACUTE PANCREATITIS

According to the revised Atlanta classification, around 2/3 of AP is categorized as mild, 20–30% moderate, and 5–10% as severe. The overall mortality is up to 6%.¹⁴ As many as 50% of patients with severe disease have a risk of mortality.^{14–16} In children, the majority of patients experience mild disease, with 15–34% developing SAP with attendant morbidity and mortality.^{19,22,31} A paucity of prospective studies is an obstacle to understanding the natural history and identification of risk stratified therapies in pediatric AP.

Biliary and alcoholic pancreatitis are the two most common causes of AP in adults,^{32,33} while pediatric cases are associated with a variety of etiologies that encompass biliary, metabolic/systemic factors, hereditary and anatomic anomalies.^{12,34–36}

In terms of risk factors in adult SAP, there have been several risk factors studied including aging, comorbidities, hypertriglyceridemia, elevated Body Mass Index (BMI), and pre-existing diabetes.³⁷ A number of scoring systems and simple laboratory markers have been developed with the aim of predicting prognosis during the early phase of AP.

Hemoconcentration, elevated blood urea nitrogen (BUN), elevated C-reactive protein (CRP), an elevated Ranson's score, APACHE (Acute Physiology And Chronic Health Evaluation) II score and SIRS have been associated with severe AP. However, the accuracy of both individual or combination of scoring systems such as BISAP (Bedside Index of Severity in Acute Pancreatitis), or the HAPS (Harmless Acute Pancreatitis Score) needs to be improved.³⁸⁻⁴⁰ To date, there is no validated pediatric severity scoring system.^{41,42} The applicability of various clinical scoring systems for intervention trials in AP is described below in the discussion on risk-stratification.

In respect to current management, early (first 24h) adequate intravenous fluid resuscitation, enteral feeding in predicted severe and severe AP, early endoscopic retrograde cholangiopancreatography (ERCP) in biliary AP with concomitant biliary obstruction or cholangitis, and delaying surgical interventions for infectious complications have been shown to be of high importance. The most common local complication is peripancreatic fluid collections, whereas the most common distant organ failure is lung injury. Importantly, centralized care improves, whereas deviation from the recommendations of the International Association of Pancreatology/American Pancreatic Association evidence-based guidelines was found to worsen, the outcome of AP.⁴³

PRECLINICAL/ANIMAL MODELS IN ACUTE PANCREATITIS RESEARCH

The pathophysiologic mechanisms of AP are not completely known.^{27,44} Mechanistic studies have been largely performed in rodent tissues as human tissue is difficult to obtain during the disease process. Recent studies in pancreatic parenchymal cells have revealed that pathobiologic pathways in rodent and human tissue are probably the same. In the context of drug development, it is important to determine the suitability of various experimental animal models for testing of potential novel therapeutic agents.

Over the past several decades, different species have been used in experimental studies,⁴⁵⁻⁵¹ but currently mice are preferred because of the availability of strains with specific genetic deletions, low cost housing and other resources related to this species.⁵²⁻⁵⁵ In the animal models, the disease is induced experimentally by common duct ligation, hyper-stimulation using cholecystokinin analogs, retrograde injection of bile acids or other chemicals or dietary modifications.⁵⁶ The end result of such insults is acute pancreatic inflammation and necrosis of varying severity with symptoms resembling clinical disease. These models have been used extensively by investigators to understand the mechanism of the disease as well as pre-clinical models for testing of therapeutic agents. Methods of induction of disease may or may not have an etiological equivalent for human disease and this limitation has often been used to criticize the relevance of a model to the human disease.⁵⁷ Using these experimental animal models, the 'Auto digestion Hypothesis' and role of 'Gall stone induced blockage of pancreatic flow or influx of bile in pancreatic duct' in biliary pancreatitis have been rigorously tested and published.⁵⁸⁻⁶¹ Based upon these studies, consensus exists regarding

the early activation of digestive enzymes in the pancreas in response to insult and pancreatic acinar cells being the primary site of initiation of injury in AP.⁶² Whether the blockage of pancreatic flow itself is sufficient in inducing AP or the influx of bile is required to trigger the disease was answered by the development of an animal model with anatomical similarity to the human pancreatic biliary ductal system.^{61,63}

Although these animal-based experimental models have helped us to understand the steps involved in the initiation and progression of the disease, there are several limitations. Human patients comprise a diverse population with different genetic backgrounds and different epigenetics and dietary preferences, which, on their own or in combination, can contribute to susceptibility, severity and progression of the disease. In animal models, full recovery is mostly observed although in patients, the disease might follow a complicated course with extended hospitalization. The distribution of bile acid surface receptors is different in rodent acinar and human cells, thereby making the applicability of the conclusions from rodent models to human disease difficult. Overall, experimental animal models are important for understanding the disease mechanism but due considerations should be given to the dissimilarities in rodent and human pancreatitis when extrapolating these findings in animals for developing strategies to treat human AP.

POTENTIAL MOLECULAR TARGETS IN AP

The current paradigm is that AP originates in injured acinar cells. Its manifestations (responses) are inappropriate, intra-acinar activation of digestive enzymes, in particular conversion of trypsinogen into active trypsin, dysregulation and inhibition of secretion, and activation of inflammatory transcription factors, followed by the inflammatory cell infiltration and necrosis, which are the major determinants of disease severity.^{4,25,26} Experimental studies strongly indicate that the inflammatory, especially neutrophilic, response in AP is non-resolving/un(der)controlled, and its down-regulation could have beneficial effects. To date, our knowledge of the inflammatory response in pancreatitis has not translated into effective therapies. One cause of non-resolving inflammation in AP could be unremitting acinar cell injury, which perpetuates the inflammatory response—a vicious cycle of parenchymal necrosis and immune cell infiltration.

Considerable progress has been achieved during the last decade in elucidating the nature of acinar cell injury leading to AP. Several critical cellular processes that become disordered in acinar cells have been elucidated and shown to drive (or even initiate) AP. In particular, pancreatitis causes disordering of autophagy, the principal catabolic cellular pathway for degradation and recycling of unneeded or dysfunctional cytoplasmic organelles.^{29,64,65} This results in accumulation in acinar cells of large vacuoles with poorly degraded cargo, a long-noted feature of pancreatitis. Impaired autophagy is a common feature of all experimental AP models and is prominent in human disease.^{29,64,65} Recent studies in genetic models^{66–69} provide mechanistic insights into the role of autophagy in pancreas: autophagy blockade or impairment triggers spontaneous pancreatitis in 4 different knockout mouse strains. These findings indicate that enhancing autophagic efficiency could be a promising approach for AP treatment. Impaired/inefficient autophagy is a common feature of various neurodegenerative diseases, and pharmacologic agents are being developed to normalize autophagy in these

diseases. These approaches should be tested for AP in pre-clinical studies. For example, it was found that the disaccharide trehalose, known to enhance autophagy and improve the outcome in neurodegenerative diseases, greatly ameliorates pathologic responses in 2 mouse models of AP.⁷⁰

Mitochondrial dysfunction is another key organelle disorder both in acinar and ductal cells found in AP.^{29,70–76} Pancreatitis causes persistent opening of a non-selective channel in the mitochondrial membrane, called the permeability transition pore (MPTP), resulting in mitochondrial depolarization and fragmentation followed by drop in ATP level – features prominent in various experimental AP models and in human disease. The protein cyclophilin D is a key mediator of MPTP opening, and studies have shown that genetic or pharmacologic knockdown of cyclophilin D abolishes or greatly reduces both local (pancreatic) and systemic pathologic responses in multiple experimental models of AP.^{29,70–72} These findings validate restoring mitochondrial function as a promising approach for AP treatment.⁷⁰ In this regard, a UK-based company, is pursuing preclinical development of cyclophilin D inhibitors for potential treatment for AP. In addition, a registered multicentre randomised double-blind clinical trial investigating the effects of high energy in the early phase of acute pancreatitis (High versus low energy administration in early phase of pancreatitis [GOULASH] trial) is currently ongoing.⁷⁷

The physiologic digestive enzyme secretion from acinar cells is mediated by oscillatory increases of cytosolic Ca^{2+} triggered in response to neurotransmitters such as acetylcholine. The increases result from Ca^{2+} released from endoplasmic reticulum (ER) stores and are transient because the released Ca^{2+} is rapidly re-uptaken into the stores. In contrast, several AP triggers, such as bile salts, or acinar cells' hyperstimulation with caerulein, cause massive and persistent Ca^{2+} release from ER stores resulting in their sustained Ca^{2+} depletion.^{78,79} In this state, the acinar cell attempts to refill ER stores by Ca^{2+} entry through the activation of the plasma membrane CRAC channel,^{78,79} resulting in sustained increase in cytosolic Ca^{2+} . Sustained increase in cytosolic Ca^{2+} causes acinar cell damage through several pathways directly or through activating the Ca^{2+} -dependent phosphatase calcineurin. For example, increase in cytosolic Ca^{2+} causes its uptake by mitochondria leading to mitochondrial Ca^{2+} overload, which in turn causes mitochondrial depolarization, decrease in ATP synthesis and, ultimately, necrosis.^{71,72} Calcineurin further exacerbates mitochondrial dysfunction by promoting mitochondrial fragmentation.⁸⁰ In addition, Ca^{2+} directly and through calcineurin stimulates activation of the proinflammatory transcription factors NF- κ B and NF-AT.⁸¹ Recent reports demonstrate that approaches to inhibit the CRAC channel or prevent calcineurin activation both attenuate experimental pancreatitis, suggesting them as important targets for disease treatment.^{78–83} The importance of calcium toxicity has also been widely investigated in pancreatic ductal cells. Bile acids, fatty acids, ethanol and even the activated trypsin have been shown to trigger two phases toxic calcium elevation causing decreased fluid and bicarbonate secretion.^{84–86} Of note, one of a series of CRAC inhibitors (developed by a U.S.-based company) has reached a phase I clinical trial.⁸⁷

Finally, pancreatic fluid and bicarbonate secretion seems to be protective against acute pancreatitis. Pancreatitis induced either aquaporin 1^{-/-}, CFTR^{-/-} or NHERF1^{-/-} mice resulted more severe pancreatitis.^{88–90} On the other hand all pancreatitis inducing factors

were shown not only damaging to the acinar cells but decreasing fluid and bicarbonate secretion as well.^{60,90,91}

Table 1, lists potential approaches for AP treatment, including normalizing autophagic and mitochondrial functions, blocking Ca²⁺ influx through CRAC channels, and inhibiting Ca²⁺-dependent phosphatase calcineurin.

RISK STRATIFICATION AND SUBJECT SELECTION

A patient is given a diagnosis of AP by meeting two out of three criteria: upper abdominal pain and symptoms suggestive of pancreatitis, serum lipase and/or amylase three times the upper limit of normal, and image findings of AP on cross-sectional imaging.^{1,2}

Identification of Complication Risk—Both local (pancreatic or peri-pancreatic) complications as well as systemic complications (distant organ failure) may occur in the setting of AP. Consensus-based definitions for complications related to AP have been previously described and incorporated into classification systems for categorizing the severity of AP.^{1,92} The most widely recognized complications of AP are pancreatic necrosis and distant organ failure (respiratory failure, renal failure, and/or circulatory shock). Both the revised Atlanta criteria and determinants-based classification systems make a distinction according to the duration of organ failure with emphasis placed on persistent (>48 hours) organ failure as the most ominous complication defining SAP.

While the frequency of major complications related to AP is relatively low, the consequences of SAP can be life-threatening. As such, substantial effort has been devoted to developing strategies for early identification of patients at increased risk for complications related to AP. Numerous approaches to risk stratification have been developed that include clinical prediction scores, biochemical parameters as well as machine learning algorithms.³⁸ A comparison of nine scoring systems in two prospectively collected cohorts of patients hospitalized for AP did not demonstrate clear advantage in terms of accuracy for any specific approach to identify patients at increased risk for persistent organ failure.³⁸ As a result, most clinical practice guidelines⁴³ currently recommend use of a simplified assessment system such as the systemic inflammatory response syndrome (SIRS) score that comprises vital signs and laboratory parameters to assess the extent of systemic inflammation related to an AP episode. It should be noted that SIRS is not specific to AP. However, previous studies have demonstrated an association between the duration of SIRS (lasting >48 hours) with persistent organ failure as well as mortality in AP.^{1,43}

Definition of Endpoints/Outcomes—Selection of study endpoints in AP should be determined based on the context of the proposed intervention. Traditional approaches for development of novel therapeutics in AP have focused on prevention of severe forms of illness. These studies incorporated initial risk-stratification to identify a higher-risk subgroup of patients for outcomes such as persistent organ failure or mortality.⁹³ In these trials, organ failure is typically defined based on an established scoring system such as the Modified Marshall Score [Atlanta] and mortality is typically defined as in-hospital death.¹

Additional outcomes to be considered in AP might include amelioration of disease or expedited recovery. Length of stay has often been reported in studies of AP.^{94,95} However, LOS is problematic as an outcome parameter as it can be influenced by factors unrelated to the disease process and is a poor overall measure of disease activity. To address these limitations, a disease-specific activity measurement scale has recently been developed through a consensus-based process.⁹⁶ This scale, the Pancreatitis Activity Scoring System or PASS comprises five domains: ability to tolerate oral intake, abdominal pain, opioid requirement, SIRS, and organ failure. Each of these components is given a weighted score with the total score represented as the sum of each individual category. The score is designed to be calculated based on 12-hour intervals to reflect dynamic changes in disease status. In a validation study using a prospective cohort of consecutively admitted patients (excluding hospital transfers) an elevated PASS at admission (>140) was shown to be associated with increased risk of moderate and severe pancreatitis while a discharge PASS >60 was associated with increased risk of early re-hospitalization.⁹⁷

Critical Path Innovation Meeting: To explore the next steps in development of clinical outcome assessment (COA) tools in AP, a Critical Path Innovation Meeting was convened with members from the FDA Center for Drug Evaluation and Research on October 26, 2017. The intent of the meeting was to learn more about the FDA drug development tool (DDT) qualification process as well as discussion regarding additional considerations for further development of the PASS instrument as a COA in AP. The findings from the meeting are intended to be available in the public domain and a summary of the meeting is included as Supplemental Digital Content 1.

Performance Characteristics of Measures—In a previous systematic literature review of clinical trials in AP involving human subjects 61 studies were identified from 1996–2014.⁹⁸ The most common primary outcome was mortality (16%). Other common outcome parameters included organ failure (15%), pancreatic infections (13%), and SIRS (10%). Included in the review were nine studies that evaluated pharmacologic intervention in AP.⁹⁸

Among these trials the Lexipifant study merits special consideration as the study design reflects most closely the established paradigm for testing early intervention in AP. In this phase III study, investigators in the United Kingdom conducted a large scale multi-center trial to evaluate the impact of early treatment (initiation of therapy within 72 hours of symptom onset) on disease course in patients with predicted severe AP.⁹³ The primary outcome measure was incidence of complications (organ failure, necrotizing pancreatitis, or acute fluid collections). The study was powered based on an assumed reduction from a 40% complication rate in the placebo arm to 24% in the intervention arm. However, after completing the trial, the investigators noted that only 14% of enrolled study participants developed new-onset organ failure. In addition, assessment of local complications (necrosis, fluid complications) was complicated by the fact that cross-sectional imaging was performed in less than half of the study participants (45% in placebo group, 38% in the intervention arm).

As a case study, the Lexipifant trial highlights several of the challenges with studying the impact of widely accepted outcome parameters such as persistent organ failure or necrosis.

In the case of the former, organ failure is a rare outcome even among patients with predicted severe disease. In the case of necrosis, this is a radiographic finding that can be problematic with respect to ascertainment given not all subjects will typically undergo cross-sectional imaging during hospitalization.

Subject Selection for Drug Trials and Time of Treatment

A major challenge in designing clinical trials for testing new drug treatments in AP relates to participant selection as well as timing of intervention. Work from previous observational studies has shown that the precision with which a patient's outcome can be predicted increases over time. However, delays in initiating therapy may limit the subsequent observable effect of an intervention. The following potential strategies address these limitations:

- *Recruitment of all potentially eligible participants with established AP irrespective of disease severity.* This trial design would be best suited for low-cost interventions intended to ameliorate the overall disease course. Advantages of this approach would include rapid accrual and the ability to initiate intervention as early as possible as well as the ability to broadly generalize the study findings to the AP population at large. Disadvantages of this approach would include limited feasibility to assess for outcomes such as persistent organ failure or necrosis given the anticipated low incidence in the general AP population.
- *Stratified randomization based on initial markers of disease severity.* Ensuring equal distribution of participants at risk for severe illness is paramount in circumstances where the impact of an intervention may vary based on the extent of disease activity (effect modification). In these settings, stratified randomization based on markers of initial disease severity available at the time of enrollment will help to ensure balanced representation across the study arms. An adaptive study design with *a priori* criteria to evaluate for feasibility can help to target further enrollment criteria following planned interim analysis.
- *Randomization following 'run-in' period.* Newly developed drugs that can prevent or diminish complications related to SAP are of critical importance. However, such agents will likely bear increased cost related to the expense associated with drug development. As a result, these newer agents will most likely be used as second-line therapy in clinical practice reserved for those patients not responding to standard resuscitation protocols. A trial design that incorporates a run-in period can be used to reflect this reality as well as enrich the study population with patients most likely to experience severe forms of AP. In this study design, eligible patients are identified at the time of presentation to the hospital but randomization only occurs once they have undergone a period of initial fluid resuscitation to evaluate for ongoing eligibility.

Logistical and Regulatory Issues in AP Related Drug Trials

A number of logistical and regulatory factors must be addressed in order to successfully conduct early intervention trials in AP. One challenge is that patients may present at various times in their disease course, which would make the initiation of therapy at an “early” stage difficult. The effect of timing with respect to onset of symptoms and initiation of therapy is an important consideration. Future trials should either incorporate the timing of symptom onset in their eligibility assessment criteria or at least carefully record this information for study participants in order to ascertain the optimal therapeutic window for future treatment.

Similar to other serious acute illnesses, caring for patients hospitalized for AP involves coordination among multiple disciplines including emergency medical teams, inpatient care services as well as potentially intensive care units or surgical teams. As a result, a successful trial requires the participation of multiple investigative teams comprising all providers that may be involved in the care of patients with AP.

Several key steps are needed to facilitate regulatory approval of new agents for treatment of acute pancreatitis. First is the development of disease-specific clinical endpoints to demonstrate efficacy of a new therapeutic intervention. An overview of the development of clinical outcome assessment as part of a drug development tool qualification program can be found at the FDA website: <https://www.fda.gov/drugs/developmentapprovalprocess/drugdevelopmenttoolsqualificationprogram>.

Types of clinical outcome assessments include patient-, clinician-, or observer-reported outcomes as well as performance outcome measures. Of particular interest are patient reported outcomes (PROs), which have not been thoroughly evaluated in AP. In addition, long-term outcomes of AP merit further consideration. With the recent observations that 15–30% of patients develop impaired glucose tolerance or diabetes within three years after a single episode of AP,^{99,100} it is important to follow patients for longer observation periods after treatment. Furthermore, recent studies have shown that the quality of life of patients remains impaired in the long term following an AP attack.¹⁰¹

RESEARCH GAPS AND OPPORTUNITIES

As the study of AP has evolved from natural history and epidemiology, to pathophysiology defined through preclinical models, to potential targets and clinical trial design, a number of factors remain, which are required to improve outcomes through the design of the next phase of human intervention studies.

- In terms of patient selection and defined outcomes, methods of defining pathobiologic pathways and severity are needed. This will allow a more “personalized” approach to therapy.
- Early prediction of SAP through novel blood and imaging biomarkers are needed.
- Patient reported outcomes (PRO) in AP are not well studied nor are PROs defined to measure the impact of AP on patients’ lives.
- PROs on pain, nutrition and quality of life should be developed for trials.

- The most important endpoints of clinical trials are death and end-organ failure, but surrogate outcomes of severity such as CRP and procalcitonin need to be validated.
- The time points for follow up ranging from inpatient admission, to recovery, to post discharge are not well defined. Long-term follow up is lacking in most studies.
- Effect of disease beyond AP such as recurrent acute pancreatitis, chronic pancreatitis, exocrine and endocrine insufficiency are poorly studied. These outcomes should be considered in study designs.
- Although most studies have focused on patients with predicted severe outcomes, including all AP patients at onset of disease may be the most appropriate approach to observe the prevention of progression to SAP, given the limitations of the prognostic scoring systems for predicting severity.

CONCLUSIONS

The workshop examined all aspects of AP from basic pathophysiology in preclinical models, and potential targets to clinical presentation, diagnosis, current management, severity predictive models to the defined outcomes. Studies that included adults as well as childhood AP were reviewed. Several gaps in the current understanding and management of AP were identified. Without addressing these gaps in designing clinical trials for treatment of AP, no further progress can be made. AP is the leading gastrointestinal disease for emergency department visits and hospitalizations, and therefore warrants further studies dedicated to target negative outcomes. The lack of animal models that mimic human disease remains a hindering factor to progress. Biomarkers to detect severity and disease pathways early on presentation are desperately needed to stratify patients with AP and allow targeted therapy designs. Future study designs should require input from regulatory agencies, focus on patient-related outcomes, develop well-defined and objective clinical outcomes to ensure progress in the management of AP that involves all stakeholders.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

The authors are grateful for the support of the National Pancreas Foundation, for consultations with members of the Food Drug Administration, and for logistical support provided by Ms. Joy Merusi of the University of Pittsburgh and Ms. Rachel Pisarski of The Scientific Consulting Group, Inc.,

Funding:

The Hungarian National Research, Development and Innovation Office (K116634, KH125678). Authors M.A.H., A.S.G., S.J.P., A.K.S., A.U., and B.U.W. acknowledge support from U01-108300 and others which represent the Consortium for the Study of Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC). MAH is supported by NIDDK, grant number 1K23DK118190-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

REFERENCES

1. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. *Gut* 2013;62:102–111. [PubMed: 23100216]
2. Morinville VD, Husain SZ, Bai H, et al. Definitions of pediatric pancreatitis and survey of present clinical practices. *J Pediatr Gastroenterol Nutr* 2012;55(3):261–265. [PubMed: 22357117]
3. Fagenholz PJ, Fernández-del Castillo C, Harris NS, et al. National study of United States emergency department visits for acute pancreatitis, 1993–2003. *BMC Emerg Med* 2007;7:1. [PubMed: 17241461]
4. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. *Gastroenterology*. 2012;143:1179–1187.e3. [PubMed: 22885331]
5. Fagenholz PJ, Castillo CF, Harris NS, et al. Increasing United States hospital admissions for acute pancreatitis, 1988–2003. *Ann Epidemiol* 2007;17(7):491–497. [PubMed: 17448682]
6. Fagenholz PJ, Fernández-del Castillo C, Harris NS, et al. Direct medical costs of acute pancreatitis hospitalizations in the United States. *Pancreas*. 2007;35:302–307. [PubMed: 18090234]
7. Roberts SE, Akbari A, Thorne K, et al. The incidence of acute pancreatitis: impact of social deprivation, alcohol consumption, seasonal and demographic factors. *Aliment Pharmacol Ther* 2013;38:539–548. [PubMed: 23859492]
8. Sellers ZM, MacIsaac D, Yu H, et al. Nationwide Trends in Acute and Chronic Pancreatitis Among Privately Insured Children and Non-elderly Adults in the United States, 2007–2014. *Gastroenterology*. 2018;155:469–478.e1. [PubMed: 29660323]
9. Morinville VD, Barmada MM, Lowe ME. Increasing incidence of acute pancreatitis at an American pediatric tertiary care center: is greater awareness among physicians responsible? *Pancreas*. 2010;39:5–8. [PubMed: 19752770]
10. Nydegger A, Heine RG, Ranuh R, et al. Changing incidence of acute pancreatitis: 10-year experience at the Royal Children's Hospital, Melbourne. *J Gastroenterol Hepatol* 2007;22:1313–1316. [PubMed: 17489962]
11. Lowe ME, Greer JB. Pancreatitis in children and adolescents. *Curr Gastroenterol Rep* 2008;10:128–135. [PubMed: 18462598]
12. Bai HX, Lowe ME, Husain SZ. What have we learned about acute pancreatitis in children? *J Pediatr Gastroenterol Nutr* 2011;52:262–270. [PubMed: 21336157]
13. Abu-El-Haija M, El-Dika S, Hinton A, et al. Acute Pancreatitis Admission Trends: A National Estimate through the Kids' Inpatient Database. *J Pediatr* 2018;194:147–151.e1. [PubMed: 29174078]
14. Mofidi R, Duff MD, Wigmore SJ, et al. Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis. *Br J Surg* 2006;93:738–744. [PubMed: 16671062]
15. Buter A, Imrie CW, Carter CR, et al. Dynamic nature of early organ dysfunction determines outcome in acute pancreatitis. *Br J Surg* 2002;89:298–302. [PubMed: 11872053]
16. Johnson CD, Abu-Hilal M. Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. *Gut* 2004;53:1340–1344. [PubMed: 15306596]
17. Phillip V, Steiner JM, Algul H. Early phase of acute pancreatitis: Assessment and management. *World J Gastrointest Pathophysiol* 2014;5:158–168. [PubMed: 25133018]
18. Binker MG, Cosen-Binker LI. Acute pancreatitis: the stress factor. *World J Gastroenterol* 2014;20:5801–5807. [PubMed: 24914340]
19. Coffey MJ, Nightingale S, Ooi CY. Serum lipase as an early predictor of severity in pediatric acute pancreatitis. *J Pediatr Gastroenterol Nutr* 2013;56:602–608. [PubMed: 23403441]
20. Lautz TB, Chin AC, Radhakrishnan J. Acute pancreatitis in children: spectrum of disease and predictors of severity. *J Pediatr Surg* 2011;46:1144–1149. [PubMed: 21683213]
21. Coffey MJ, Nightingale S, Ooi CY. Serum lipase as an early predictor of severity in pediatric acute pancreatitis. *J Pediatr Gastroenterol Nutr* 2013;56:602–608. [PubMed: 23403441]

22. DeBanto JR, Goday PS, Pedroso MR, et al. Acute pancreatitis in children. *Am J Gastroenterol* 2002;97:1726–1731. [PubMed: 12135026]
23. Szabo FK, Hornung L, Oparaji JA, et al. A prognostic tool to predict severe acute pancreatitis in pediatrics. *Pancreatology*. 2016;16:358–364. [PubMed: 27051062]
24. Zsoldos F, Parniczky A, Mosztbacher D, et al. Pain in the Early Phase of Pediatric Pancreatitis (PINEAPPLE Trial): Pre-Study Protocol of a Multinational Prospective Clinical Trial. *Digestion*. 2016;93:121–126. [PubMed: 26641250]
25. Pandol SJ, Saluja AK, Imrie CW, et al. Acute pancreatitis: bench to the bedside. *Gastroenterology*. 2007;132:1127–1151. [PubMed: 17383433]
26. Sah RP, Dawra RK, Saluja AK. New insights into the pathogenesis of pancreatitis. *Curr Opin Gastroenterol* 2013;29:523–530. [PubMed: 23892538]
27. Sah RP, Saluja A. Molecular mechanisms of pancreatic injury. *Curr Opin Gastroenterol* 2011;27:444–451. [PubMed: 21844752]
28. Waterford SD, Kolodecik TR, Thrower EC, Gorelick FS. Vacuolar ATPase regulates zymogen activation in pancreatic acini. *J Biol Chem* 2005;280:5430–5434. [PubMed: 15582989]
29. Gukovskaya AS, Pandol SJ, Gukovsky I. New insights into the pathways initiating and driving pancreatitis. *Curr Opin Gastroenterol* 2016;32:429–435.
30. Szentesi A, Toth E, Balint E, et al. Analysis of Research Activity in Gastroenterology: Pancreatitis Is in Real Danger. *PLoS One*. 2016;11:e0165244. [PubMed: 27776171]
31. Lautz TB, Chin AC, Radhakrishnan J. Acute pancreatitis in children: spectrum of disease and predictors of severity. *J Pediatr Surg* 2011;46:1144–1149. [PubMed: 21683213]
32. Yadav D, Whitcomb DC. The role of alcohol and smoking in pancreatitis. *Nat Rev Gastroenterol Hepatol* 2010;7:131–145. [PubMed: 20125091]
33. Wang GJ, Gao CF, Wei D, et al. Acute pancreatitis: etiology and common pathogenesis. *World J Gastroenterol* 2009;15:1427–1430. [PubMed: 19322914]
34. Park AJ, Latif SU, Ahmad MU, et al. A comparison of presentation and management trends in acute pancreatitis between infants/toddlers and older children. *J Pediatr Gastroenterol Nutr* 2010;51:167–170. [PubMed: 20479687]
35. Lopez MJ. The changing incidence of acute pancreatitis in children: a single-institution perspective. *J Pediatr* 2002;140:622–624. [PubMed: 12032533]
36. Parniczky A, Abu-El-Haija M, Husain S, et al. EPC/HPSG evidence-based guidelines for the management of pediatric pancreatitis. *Pancreatology*. 2018;18:146–160. [PubMed: 29398347]
37. Parniczky A, Kui B, Szentesi A, et al. Prospective, Multicentre, Nationwide Clinical Data from 600 Cases of Acute Pancreatitis. *PLoS One*. 2016;11:e0165309. [PubMed: 27798670]
38. Mounzer R, Langmead CJ, Wu BU, et al. Comparison of existing clinical scoring systems to predict persistent organ failure in patients with acute pancreatitis. *Gastroenterology*. 2012;142:1476–1482; quiz e15-e16. [PubMed: 22425589]
39. Wu BU, Johannes RS, Sun X, Tabak Y, et al. The early prediction of mortality in acute pancreatitis: a large population-based study. *Gut* 2008;57:1698–1703. [PubMed: 18519429]
40. Lankisch PG, Weber-Dany B, Hebel K, et al. The harmless acute pancreatitis score: a clinical algorithm for rapid initial stratification of nonsevere disease. *Clin Gastroenterol Hepatol* 2009;7:702–705; quiz 607. [PubMed: 19245846]
41. Uc A Predicting the severity of pediatric acute pancreatitis: are we there yet? *J Pediatr Gastroenterol Nutr* 2013;56:584–585. [PubMed: 23535763]
42. Abu-El-Haija M, Lin TK, Palermo J. Update to the management of pediatric acute pancreatitis: highlighting areas in need of research. *J Pediatr Gastroenterol Nutr* 2014;58:689–693. [PubMed: 24614126]
43. Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. *Pancreatology*. 2013;13(4 Suppl 2):e1–e15. [PubMed: 24054878]
44. Simeone DM, Pandol SJ. The pancreas: biology, diseases, and therapy. *Gastroenterology*. 2013;144:1163–1165. [PubMed: 23622124]

45. Lampel M, Kern HF. Acute interstitial pancreatitis in the rat induced by excessive doses of a pancreatic secretagogue. *Virchows Arch A Pathol Anat Histol* 1977;373:97–117. [PubMed: 139754]
46. Saluja A, Saluja M, Villa A, et al. Pancreatic duct obstruction in rabbits causes digestive zymogen and lysosomal enzyme colocalization. *J Clin Invest* 1989;84:1260–1266. [PubMed: 2477393]
47. Merkord J, Jonas L, Weber H, Kroning G, et al. Acute interstitial pancreatitis in rats induced by dibutyltin dichloride (DBTC): pathogenesis and natural course of lesions. *Pancreas*. 1997;15:392–401. [PubMed: 9361094]
48. Senninger N, Moody FG, Coelho JC, et al. The role of biliary obstruction in the pathogenesis of acute pancreatitis in the opossum. *Surgery*. 1986;99:688–693. [PubMed: 2424109]
49. Wang Y, Kayoumu A, Lu G, et al. Experimental Models in Syrian Golden Hamster Replicate Human Acute Pancreatitis. *Sci Rep* 2016;6:28014. [PubMed: 27302647]
50. Rakonczay Z, Jr, Hegyi P, Dosa S, et al. A new severe acute necrotizing pancreatitis model induced by L-ornithine in rats. *Crit Care Med* 2008;36:2117–2127. [PubMed: 18594222]
51. Hegyi P, Rakonczay Z, Jr, Sari R, et al. L-arginine-induced experimental pancreatitis. *World J Gastroenterol*. 2004;10:2003–2009. [PubMed: 15237423]
52. Dawra R, Sharif R, Phillips P, et al. Development of a new mouse model of acute pancreatitis induced by administration of L-arginine. *Am J Physiol Gastrointest Liver Physiol* 2007;292:G1009–G1018. [PubMed: 17170029]
53. Perides G, van Acker GJ, Laukkarinen JM, et al. Experimental acute biliary pancreatitis induced by retrograde infusion of bile acids into the mouse pancreatic duct. *Nat Protoc* 2010;5:335–341. [PubMed: 20134432]
54. Samuel I, Yuan Z, Meyerholz DK, et al. A novel model of severe gallstone pancreatitis: murine pancreatic duct ligation results in systemic inflammation and substantial mortality. *Pancreatology*. 2010;10:536–544. [PubMed: 20975317]
55. Lombardi B, Estes LW, Longnecker DS. Acute hemorrhagic pancreatitis (massive necrosis) with fat necrosis induced in mice by DL-ethionine fed with a choline-deficient diet. *Am J Pathol* 1975;79:465–480. [PubMed: 1094837]
56. Lerch MM, Gorelick FS. Models of acute and chronic pancreatitis. *Gastroenterology*. 2013;144:1180–1193. [PubMed: 23622127]
57. Gorelick FS, Lerch MM. Do Animal Models of Acute Pancreatitis Reproduce Human Disease? *Cell Mol Gastroenterol Hepatol* 2017;4:251–262. [PubMed: 28752114]
58. Hegyi P, Maleth J, Walters JR, et al. Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease. *Physiol Rev* 2018;98:1983–2023. [PubMed: 30067158]
59. Hegyi P Bile as a key aetiological factor of acute but not chronic pancreatitis: a possible theory revealed. *J Physiol* 2016;594:6073–6074. [PubMed: 27800624]
60. Venglovecz V, Rakonczay Z, Jr, Ozsvari B, et al. Effects of bile acids on pancreatic ductal bicarbonate secretion in guinea pig. *Gut* 2008;57:1102–1112. [PubMed: 18303091]
61. Takacs T, Rosztoczy A, Maleth J, et al. Intraductal acidosis in acute biliary pancreatitis. *Pancreatology*. 2013;13:333–335. [PubMed: 23890129]
62. Hegyi P, Petersen OH. The exocrine pancreas: the acinar-ductal tango in physiology and pathophysiology. *Rev Physiol Biochem Pharmacol* 2013;165:1–30. [PubMed: 23881310]
63. Lerch MM, Saluja AK, Runzi M, Dawra R, Saluja M, Steer ML. Pancreatic duct obstruction triggers acute necrotizing pancreatitis in the opossum. *Gastroenterology*. 1993;104:853–861. [PubMed: 7680018]
64. Gukovskaya AS, Gukovsky I. Autophagy and pancreatitis. *Am J Physiol Gastrointest Liver Physiol* 2012;303:G993–G1003. [PubMed: 22961802]
65. Gukovskaya AS, Gukovsky I, Algul H, et al. Autophagy, Inflammation, and Immune Dysfunction in the Pathogenesis of Pancreatitis. *Gastroenterology*. 2017;153:1212–1226. [PubMed: 28918190]
66. Antonucci L, Fagman JB, Kim JY, et al. Basal autophagy maintains pancreatic acinar cell homeostasis and protein synthesis and prevents ER stress. *Proc Natl Acad Sci U S A* 2015;112:E6166–E6174. [PubMed: 26512112]

67. Diakopoulos KN, Lesina M, Wormann S, et al. Impaired autophagy induces chronic atrophic pancreatitis in mice via sex- and nutrition-dependent processes. *Gastroenterology*. 2015;148:626–638.e17. [PubMed: 25497209]
68. Li N, Wu X, Holzer RG, et al. Loss of acinar cell IKK α triggers spontaneous pancreatitis in mice. *J Clin Invest* 2013;123:2231–2243. [PubMed: 23563314]
69. Mareninova OA, Sendler M, Malla SR, et al. Lysosome associated membrane proteins maintain pancreatic acinar cell homeostasis: LAMP-2 deficient mice develop pancreatitis. *Cell Mol Gastroenterol Hepatol* 2015;1:678–694. [PubMed: 26693174]
70. Biczó G, Vegh ET, Shalbueva N, et al. Mitochondrial dysfunction, through impaired autophagy, leads to endoplasmic reticulum stress, deregulated lipid metabolism, and pancreatitis in animal models. *Gastroenterology*. 2018;154:689–703. [PubMed: 29074451]
71. Mukherjee R, Mareninova OA, Odinkova IV, et al. Mechanism of mitochondrial permeability transition pore induction and damage in the pancreas: inhibition prevents acute pancreatitis by protecting production of ATP. *Gut* 2016;65:1333–1346. [PubMed: 26071131]
72. Shalbueva N, Mareninova OA, Gerloff A, et al. Effects of oxidative alcohol metabolism on the mitochondrial permeability transition pore and necrosis in a mouse model of alcoholic pancreatitis. *Gastroenterology*. 2013;144:437–446.e6. [PubMed: 23103769]
73. Biczó G, Hegyi P, Dosa S, et al. The crucial role of early mitochondrial injury in L-lysine-induced acute pancreatitis. *Antioxid Redox Signal* 2011;15:2669–2681 [PubMed: 21644850]
74. Maléth J, Hegyi P. Ca²⁺ toxicity and mitochondrial damage in acute pancreatitis: translational overview. *Philos Trans R Soc Lond B Biol Sci* 2016;371. pii: 20150425.
75. Maléth J, Hegyi P, Rakonczay Z, Jr, et al. Breakdown of bioenergetics evoked by mitochondrial damage in acute pancreatitis: Mechanisms and consequences. *Pancreatol*. 2015;15(4 Suppl):S18–S22. [PubMed: 26162756]
76. Maléth J, Rakonczay Z, Jr, Venglovecz V, et al. Central role of mitochondrial injury in the pathogenesis of acute pancreatitis. *Acta Physiol (Oxf)*. 2013;207:226–235. [PubMed: 23167280]
77. Marta K, Szabo AN, Pecci D, et al. High versus low energy administration in the early phase of acute pancreatitis (GOULASH trial): protocol of a multicentre randomised double-blind clinical trial. *BMJ Open*. 2017;7:e015874.
78. Gerasimenko JV, Gryshchenko O, Ferdek PE, et al. Ca²⁺ release-activated Ca²⁺ channel blockade as a potential tool in antipancreatitis therapy. *Proc Natl Acad Sci U S A* 2013;110:13186–13191. [PubMed: 23878235]
79. Wen L, Voronina S, Javed MA, et al. Inhibitors of ORAI1 prevent cytosolic calcium-associated injury of human pancreatic acinar cells and acute pancreatitis in 3 mouse models. *Gastroenterology*. 2015;149:481–492.e7. [PubMed: 25917787]
80. Cereghetti GM, Stangherlin A, Martins de Brito O, et al. Dephosphorylation by calcineurin regulates translocation of Drp1 to mitochondria. *Proc Natl Acad Sci U S A* 2008;105:15803–15808. [PubMed: 18838687]
81. Jin S, Orabi AI, Le T, et al. Exposure to radiocontrast agents induces pancreatic inflammation by activation of nuclear factor- κ B, calcium signaling, and calcineurin. *Gastroenterology*. 2015;149:753–764.e11. [PubMed: 25980752]
82. Orabi AI, Wen L, Javed TA, et al. Targeted inhibition of pancreatic acinar cell calcineurin is a novel strategy to prevent post-ERCP pancreatitis. *Cell Mol Gastroenterol Hepatol* 2017;3:119–128. [PubMed: 28090570]
83. Wen L, Javed TA, Yimlamai D, et al. Transient High Pressure in Pancreatic Ducts Promotes Inflammation and Alters Tight Junctions via Calcineurin Signaling in Mice. *Gastroenterology*. 2018 6 18. [Epub ahead of print].
84. Pallagi P, Venglovecz V, Rakonczay Z, Jr, et al. Trypsin reduces pancreatic ductal bicarbonate secretion by inhibiting CFTR Cl⁻ channels and luminal anion exchangers. *Gastroenterology*. 2011;141:2228–2239.e6. [PubMed: 21893120]
85. Hegyi P Blockade of calcium entry provides a therapeutic window in acute pancreatitis. *J Physiol* 2016;594:257. [PubMed: 26767885]
86. Maléth J, Hegyi P. Calcium signaling in pancreatic ductal epithelial cells: an old friend and a nasty enemy. *Cell Calcium* 2014;55:337–345. [PubMed: 24602604]

87. Tian C, Du L, Zhou Y, et al. Store-operated CRAC channel inhibitors: opportunities and challenges. *Future Med Chem* 2016;8:817–832. [PubMed: 27149324]
88. Venglovecz V, Pallagi P, Kemeny LV, et al. The Importance of Aquaporin 1 in Pancreatitis and Its Relation to the CFTR Cl(–) Channel. *Front Physiol* 2018;9:854. [PubMed: 30050452]
89. Pallagi P, Balla Z, Singh AK, et al. The role of pancreatic ductal secretion in protection against acute pancreatitis in mice*. *Crit Care Med* 2014;42:e177–e188. [PubMed: 24368347]
90. Maléth J, Balázs A, Pallagi P, et al. Alcohol disrupts levels and function of the cystic fibrosis transmembrane conductance regulator to promote development of pancreatitis. *Gastroenterology*. 2015;148:427–439.e16. [PubMed: 25447846]
91. Pallagi P, Hegyi P, Rakonczay Z, Jr. The Physiology and Pathophysiology of Pancreatic Ductal Secretion: The Background for Clinicians. *Pancreas*. 2015;44:1211–1233. [PubMed: 26465950]
92. Dellinger EP, Forsmark CE, Layer P, et al. Determinant-based classification of acute pancreatitis severity: an international multidisciplinary consultation. *Ann Surg* 2012;256:875–880. [PubMed: 22735715]
93. Johnson CD, Kingsnorth AN, Imrie CW, et al. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. *Gut* 2001;48:62–69. [PubMed: 11115824]
94. Eckerwall GE, Tingstedt BB, Bergenzaun PE, et al. Immediate oral feeding in patients with mild acute pancreatitis is safe and may accelerate recovery--a randomized clinical study. *Clin Nutr* 2007;26:758–763. [PubMed: 17719703]
95. Szabo FK, Fei L, Cruz LA, et al. Early Enteral Nutrition and Aggressive Fluid Resuscitation are Associated with Improved Clinical Outcomes in Acute Pancreatitis. *J Pediatr*. 2015;167:397–402.e1. [PubMed: 26210842]
96. Wu BU, Batech M, Quezada M, et al. Dynamic Measurement of Disease Activity in Acute Pancreatitis: The Pancreatitis Activity Scoring System. *Am J Gastroenterol* 2017;112:1144–1152. [PubMed: 28462914]
97. Buxbaum J, Quezada M, Chong B, et al. The Pancreatitis Activity Scoring System predicts clinical outcomes in acute pancreatitis: findings from a prospective cohort study. *Am J Gastroenterol* 2018;113:755–764. [PubMed: 29545634]
98. Afghani E, Pandol SJ, Shimosegawa T, et al. Acute Pancreatitis-Progress and Challenges: A Report on an International Symposium. *Pancreas*. 2015;44:1195–1210. [PubMed: 26465949]
99. Das SL, Singh PP, Phillips AR, et al. Newly diagnosed diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis. *Gut* 2014;63:818–831. [PubMed: 23929695]
100. Yuan L, Tang M, Huang L, et al. Risk Factors of Hyperglycemia in Patients After a First Episode of Acute Pancreatitis: A Retrospective Cohort. *Pancreas*. 2017;46:209–218. [PubMed: 27846145]
101. Machicado JD, Gougol A, Stello K, et al. Acute Pancreatitis Has a Long-term Deleterious Effect on Physical Health Related Quality of Life. *Clin Gastroenterol Hepatol* 2017;15:1435–1443.e2. [PubMed: 28579182]

Table 1.

Potential Molecular Targets for AP Therapy

Cellular Process to Target	Association With AP			
	Experimental	Human	Genetic Approaches	Pharmacologic Approaches
Impaired Autophagy	Shown in 10 experimental and genetic pancreatitis models	Associated with human disease	Genetic approaches to block autophagy trigger spontaneous pancreatitis in 4 genetic mouse models	Enhancing autophagy efficiency with trehalose prevented or alleviated pathologic responses in 2 mouse models in AP
Mitochondrial Dysfunction	Shown in 9 experimental and genetic pancreatitis models	Associated with human disease	Genetic approaches to restore mitochondrial function ameliorate AP in all models tested	Pharmacologic approaches to restore mitochondrial function greatly ameliorated AP severity in 4 models tested
Excessive Ca ²⁺ Influx	Shown in at least in 3 experimental pancreatitis models	?	?	Pharmacologic approaches to block CRAC channel alleviate AP in 3 models tested
Calcineurin Activation	Shown in a mouse model of post-ERCP pancreatitis	?	Genetic approaches to block calcineurin alleviate inflammation	Pharmacologic approaches to inhibit calcineurin alleviate inflammation in a mouse model
CFTR	Shown in at least in 3 pancreatitis models	Associated with human disease	Deletion of CFTR in at least 3 animal models trigger spontaneous pancreatitis	VX-770 and VX-809 restore the expression cystic fibrosis transmembrane conductance regulator of CFTR